Overview

Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients

Status:
Completed

Trial end date:
2020-03-23

Target enrollment:

Participant gender:

Summary

Phase I/II, Multicenter, Open Label, Clinical Trial to evaluate safety and efficacy and determine the Maximum Tolerated Dose (MTD) of Filanesib in combination with pomalidomide and dexamethasone in relapsed/refractory (R/R) Multiple Myeloma (MM) patients

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

PETHEMA Foundation

Collaborators:

Array BioPharma
Celgene Corporation

Treatments:

BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Filanesib
Pomalidomide
Thalidomide